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Abstract
Autoimmune hepatitis (AIH) is an autoimmune liver disease that is characterized by a progressive destruction of the liver parenchyma
and the development of liver ﬁbrosis. We aimed to examine the relationship between circulating cytokines/chemokines and the Mac-
2 binding protein glycosylation isomer (M2BPGi) levels in Japanese patients with autoimmune hepatitis (AIH).
We investigated the relationship between circulating cytokines/chemokines and M2BPGi levels in Japanese patients with AIH.
Seventy-seven patients with well-documented AIH were enrolled in the National Hospital Organization (NHO)-AIH-liver-network
database. We measured the serum levels of 20 cytokines in 31 selected AIH patients before and after steroid treatment using
multisuspension cytokine array.
Eleven cytokines and soluble adhesion molecules were increased in untreated AIH patients compared with treated AIH patients.
Among these cytokines and soluble adhesion molecules, soluble intercellular adhesion molecule-1 (sICAM-1) and interferon-
g-inducible protein 10 (IP-10) were most downregulated by steroid therapy in AIH patients. We measured serum sICAM-1 and IP-10
by ELISA and found the levels were signiﬁcantly higher in AIH patients (n=77) comparedwith chronic viral hepatitis C patients (n=32).
Furthermore, there was a positive correlation between sICAM-1 or IP-10 and alanine aminotransferase, total bilirubin, and circulating
M2BPGi levels. M2BPGi levels were increased in AIH patients with high stages of liver ﬁbrosis. Additionally, M2BPGi levels were
correlated with the histological grade of inﬂammation in AIH. Circulating M2BPGi levels were signiﬁcantly reduced by steroid
treatment in AIH patients.
sICAM-1 and IP-10 are useful markers to assess immune-mediated hepatitis activity in AIH and they correlate with circulating
M2BPGi. Serum M2BPGi levels increased in untreated AIH patients with active hepatitis and were decreased by steroid therapy.
M2BPGi reﬂects autoimmune-mediated hepatic inﬂammation as well as liver ﬁbrosis.
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1. Introduction
Autoimmune hepatitis (AIH) is an immune-mediated liver disease
characterized by elevated serum-IgG and circulating autoanti-
bodies.[1] Corticosteroids alone or in combination with immu-
nosuppressants are the mainstay therapies for patients with
AIH.[2] In most cases, these therapies result in biochemical
remission, a treatment end-point in AIH.[3] However, some AIH
patients develop liver cirrhosis and liver failure at initial
presentation.[4,5] Hepatic inﬂammation is regulated by the
activities of immune cells including lymphocytes, Kupffer cells,
hepatocytes, and hepatic stellate cells.[6] Serum cytokines/
chemokines are thought to be linked to the pathogenesis of
AIH by activating these hepatic immune cells.[7] Previous studies
reported that levels of circulating inﬂammatory cytokines/
chemokines reﬂect liver damage in patients with AIH.[8]
However, the relationship between cytokines/chemokines and
hepatic inﬂammation in AIH patients remains unresolved.
Mac-2 binding protein glycosylation isomer (M2BPGi) is a
serum biomarker for liver ﬁbrosis caused by chronic viral
hepatitis and nonalcoholic fatty liver disease.[9,10] Although
M2BPGi levels are correlated with liver ﬁbrosis, serum M2BPGi
values are increased in patients with acute liver injury suggesting
M2BPGi may reﬂect liver inﬂammation.[11] More recently,
Umemura et al reported that M2BPGi levels represented a
simple and reliable surrogate marker of liver ﬁbrosis in patients
with primary biliary cholangitis (PBC).[12] Nishikawa et al also
reported that M2BPGi was a useful marker for assessing liver
histological ﬁndings in AIH patients.[13] However, there is no
available data regarding the effects of immunosuppressive
treatments on M2BPGi levels in patients with AIH.
In the present study, we analyzed the serum levels of cytokines/
chemokines and examined the relationship between these
cytokines and clinical parameters to elucidate putative biomark-
ers for immune-mediated liver injury in patients with AIH.
Another aim of the present study was to examine the relationship
between M2BPGi levels and inﬂammatory cytokines and liver
histological ﬁndings in patients with AIH.
2. Patients and methods
2.1. Study population
Patients with well-documented and untreated AIH were enrolled
from the National Hospital Organization (NHO)-AIH-liver-
network database, a multicenter registry for Japanese patients
with AIH.[5] The diagnosis of AIH was made according to the
diagnostic criteria deﬁned by International Autoimmune Hepati-
tis Group[14], including a raised IgG level and presence of organ-
speciﬁc and non-organ-speciﬁc autoantibodies, presence of
interface hepatitis and portal plasma cell inﬁltration on liver
histology and the absence of other liver diseases of known
etiology. Patients were excluded from the study if there was
histological evidence of cholangitis or non-alcoholic steatohe-
patitis. Patients positive for hepatitis B virus surface antigen or
HCVRNAwere also excluded. Patients with other causes of liver
disease, such as excess alcohol or drug use, were excluded based
on reviews of their appropriate history and investigations. As
controls, patients with chronic hepatitis C (untreated CHC, n=
32; female/male=16/16; mean age, 56.2±7.8 years; aspartate
aminotransferase (AST), 43.4±23.6 IU/L; alanine transaminase
(ALT), 54.1±39.0 IU/L), total bilirubin (TB), 0.8±0.4mg/d were
included. As controls for autoimmune disease, SLE patients (n=
27; female/male=22/5; untreated SLE=12) satisfying American
College of Rheumatology classiﬁcation criteria were included.
Mean age was 35.2±13.4 years, mean age at diagnosis was 30.0
±12.5 years, mean disease duration 4.5±5.6 years. Aspartate
aminotransferase (AST), 38.1±35.5 IU/L; alanine transaminase
(ALT), 38.4±72.9 IU/L); total bilirubin (TB), 0.8±0.8mg/d.
Fifteen patients had been treated with steroid (mean prednisolone
doses; 21.3±21.9mg/day), and 9 patients had been treated with
steroid plus immunosuppressive agents. Nine patients were
complicated with lupus nephritis and 6 patients were complicated
with neuropsychiatric SLE (NPSLE). The study was approved by
the Ethics Committee of the NHOCentral Internal Review Board
and participating NHO liver-network hospitals. Written in-
formed consent was obtained from each individual.
2.2. Multiplex cytokine assay
We performed a multiplex cytokine bead assay blindly and in
parallel using the Bio-plex Pro Human Cytokine assay (Bio-Rad,
Hercules, CA) and Milliplex MAP Human Cytokine/Chemokine
panel 1 (Millipore, Billerica, MA) according to the manufac-
turers’ instructions as described previously.[15] The subjects’
baseline demographic characteristics were compared using
Fisher’s exact test for discrete variables and the Wilcoxon test
for continuous variables. The Kruskal–Wallis test followed by
Dunn’s multiple comparisons test was used to compare cytokine
levels between groups. To rank the cytokine levels, we performed
a multivariate classiﬁcation algorithm termed random forest
analysis (RFA),[16] using the R package RandomForest (http://
cran.r-project.org/web/packages/randomForest/) ver. 4.6–12
software, as previously described.[17]
2.3. Enzyme-linked immunosorbent assay for sICAM-1and
IP-10
Serum concentrations of sICAM-1and IP-10 were measured
using human sICAM-1 or IP-10 immunoassay kit (R&DSystems,
Minneapolis, MN) according to the manufacturer’s instruction.
2.4. Measurement of M2BPGi
Serum M2BPGi level was directly measured with the HISCL
M2BPGi reagent kit (Sysmex, Kobe, Japan) using an automatic
immunoanalyzer HISCL-5000 (Sysmex, Hyogo, Japan).
M2BPGi levels were indexed using the following equation:
Cut-off Index (C.O.I.)= ([M2BPGi]sample-[M2BPGi]NC)/
([M2BPGi]PC)-[M2BPGi]NC), where [M2BPGi]sample repre-
sents the M2BPGi count of the serum sample, PC is positive
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control, and NC is negative control. The positive control was
supplied as a calibration solution standardized to yield a C.O.I. of
1.0. The positive control was supplied as a calibration solution.
The range of measurement is 0.1 to 20 COI[18].
2.5. Staging of hepatic ﬁbrosis
Liver biopsies were taken by ﬁne-needle aspiration (16G or 18G
sonopsy) guided by US. Liver tissue specimens were ﬁxed in 10%
formalin, embedded in parafﬁn, and stained with hematoxylin
and eosin. They were evaluated for hepatic ﬁbrosis stage by a
pathologist according to the criteria of Desmet et al.[19]
2.6. Statistical analysis
The Chi-square test and Mann–Whitney U tests were applied to
detect signiﬁcant associations. Correlations between continuous
variables were analyzed by the Pearson correlation test. Results
for non-normally distributed continuous variables were summa-
rized as mean or medians (interquartile ranges) and were
compared by the Mann–Whitney U test. Paired data were
analyzed by non-parametric tests using theWilcoxon signed-rank
test for the comparison of paired data.
3. Results
3.1. Baseline characteristics of patients
The demographic data of the enrolled AIH patients are shown in
Table 1. There were 14 males and 63 females with a median
(range) age of 64 (21–83) years. Using the AIH scoring system,[14]
49 patients had more than 15 points (deﬁnite AIH) and the
remaining 28 patients had 10 to 15 points (probable AIH).
Regarding histological ﬁndings, in terms of the degree of
inﬂammation activity, A3 was observed in 37 patients, A2 in
27 and A1 in 11. In terms of liver ﬁbrosis stage, F4 was observed
in 1 patient, F3 in 24, F2 in 14, F1 in 33, and F0 in 3. The
M2BPGi values (pretreatment) in all AIH patients ranged
between 0.33 and 16.9 (mean value 4.87). In 2 patients, liver
biopsy was not performed due to medical reasons.
3.2. Identiﬁcation of combinational biomarkers speciﬁc for
AIH in attack by Random Forest Analysis and Logistic
Regression Analysis
We selected 31 untreated AIH patients with paired serum samples
before and after treatment and measured their serum levels of
multiple cytokine/chemokines using the multiplex cytokine bead
assay. The serum levels of 11 cytokines (IL-4, IL-8, IL-10, IL-18,
TNF-a, sICAM-1, sVCAM-1, CCL-3, CCL-4 CCL-22, and
CXCL10) were signiﬁcantly elevated in the untreated AIH
patients compared with those receiving 4 weeks of steroid
therapy (Table 2). To determine the most important predictor to
discriminate untreated active AIH from treated inactive AIH, we
ranked the cytokines by importance using the random forest
analysis (RFA). Hierarchical clustering with heatmaps based on
the Spearman correlation coefﬁcients between active AIH and
inactive AIH (Fig. 1). Although the exact identity of T cells that
contribute to pathogenesis of AIH remains unknown, possible
alterations in theTh1 (cellular immunity) and Th2 (humoral
immunity) balance may play a role in liver cell injury.[20] It
appears that an increased Th2 cytokines, such IL-10, IL-4 and
proinﬂammatory cytokines/chemokines are increased in untreat-
ed AIH patients,[7] whereas we focused on the cytokines most
Table 1
Baseline characteristics of 77 Japanese autoimmune hepatitis
(AIH) Type 1 patients.
Characteristics n=77
Female, n/total (%) 63 (81.8)
Age, y, mean±SD 63.0±12.3
Biochemistry
AST, IU/L, median (IQR) 471.8 (11–2010)
ALT, IU/L, median (IQR) 607.5 (12–2426)
ALP, IU/L, median (IQR) 450.9 (123–1208)
Total Bilirubin, mg/dl, median (IQR) 4.5 (0.4–25.1)
Albumin, g/dl, median (IQR) 3.9 (2.4–5.0)
IgG, mg/dl, median (IQR) 2361.2 (923–4966)
Prothrombin time, %, median (IQR) 82.6 (37.8–122.7)
Platelets, 104/ml, median (IQR) 18.9 (3.4–40.4)
Serology
ANA ≧1:40, n/total (%) 52/77 (67.5)
ASMA ≧1:40, n/total (%) 43/67 (64.2)
Histology
Cirrhosis, n/total (%) 9/77 (11.7)
IAIHG criteria
Score, median (IQR) 16.4 (9–22)
Prednisolone use,n (%) 75 (97.4)
Other immunosuppressant use,n (%) 11 (14.3)
UDCA use,n (%) 23 (29.9)
Cirrhosis,n (%) 9 (11.7)
Complications of collagen disease,n(%) 18 (11.0)
Fibrosis(N)F0/F1/F2/F3/F4 75 3/33/14/20/5
Activity(N)A0/A1/A2/A3 75 0/11/27/37
ALP= alkaline phosphate, ALT= alanine aminotransferase, ANA= anti-nuclear antibody, ASMA=
anti-smooth muscle antibody, AST=aspartate aminotransferase, IAIHG= International Autoimmune
Hepatitis Group, IgG= immunoglobulin G, IQR= interquartile range, UDCA=ursodeoxycholic acid.
Table 2
Cytokine proﬁle of autoimmune hepatitis (AIH) patients pre or post
treatment pg/ml (
∗
ng/ml).
Cytokine
AIH pre-treatment
(n=31)
AIH post-
treatment (n=31)
P-value (pre-vs-
post-treatment)
IL-4 30.32 (2.8–84.0) 11.08 (0.1–47.5) .036
IL-6 0.1 (0.1–1.3) 0.1 (0.1–0.2) .79
IL-8 44.6 (7.4–26.8) 18.3 (7.4–26.8) .004
IL-10 25.74 (13.4–55.1) 0.1 (0.1–4.5) <.0001
IL-17 2.5 (0.1–5.0) 1.0 (0.1–3.9) .67
IL-18 622 (391–1007) 258 (176–436) <.0001
TNF-a 18.6 (13.5–29.7) 7.8 (4.5–10.1) <.0001
IFN-g 6.9 (3.4–14.3) 5.3 (1.0–10.3) .58
GM-CSF 4.2 (0.6–9.3) 1.1 (0.1–7.3) .31
G-CSF 12.8 (0.1–32.3) 20.1 (11.4–44.2) .75
VEGF 107 (0.1–136) 43.7 (0.1–166) .58
SICAM-1
∗
745 (504–945) 163 (131–259) <.0001
SVCAM-1
∗
367 (293–446) 201 (165–267) <.0001
FGF2 27.7 (10.6–48.6) 10.6 (0.1–38.8) .26
CCL2 673 (379–910) 642 (373–978) .95
CCL3 22.0 (11.5–32.5) 7.1 (0.1–24.4) .010
CCL4 97.2 (72.6–146) 54.9 (31.0–89.0) .0096
CCL22 410 (352–600) 215 (147–291) <.0001
CXCL1 792 (576–1111) 682 (445–843) .24
CXCL10 4461 (2310–5354) 631 (393–1215) <.0001
P-values ware established using Kruskal–Wallist test followed by a Dunn multiple comparisons test.
Bold indicates signiﬁcant Values. G-CSF=granulocyte colony stimulating factor, GM-CSF=
granulocyte macrophage colony stimulating factor, IFN= interferon, TNF-a= tumor necrosis factor-
alpha, VEGF= vascular endothelial growth factor.
∗
Values are the median (interquartile range) pg/ml.
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downregulated by steroid treatment, sICAM-1 and CXCL-10
(interferon-g-inducible protein 10;IP-10). We subsequently
measured the serum concentrations of sICAM-1 and IP-10 in
all AIH patients by speciﬁc ELISAs (Fig. 2). Serum levels of
sICAM-1 and IP-10were elevated in AIH patients compared with
chronic hepatitis C patients (sICAM-1; AIH: 1732.8±1076.8ng/
ml, CHC: 605.7±85.7ng/ml, IP-10; AIH: 914.5±732.6pg/ml,
CHC: 487.9±356.8pg/ml) or SLE patients (sICAM-1; 461.4±
157.1ng/ml, IP-10;735.6±870.6pg/ml).
3.3. Relationship between circulating sICAM-1 and IP-10
and liver function tests
To investigate the relationship between sICAM-1 or IP-10 and
standard liver function parameters, we examined correlations
between circulating sICAM-1 and serum levels of ALT or TB. A
positive correlation was observed between serum levels of
sICAM-1 and ALT or TB (Fig. 3). Similarly, a positive correlation
was observed between serum levels of IP-10 and ALT or TB
(Fig. 4).
3.4. Relationship between M2BPGi and liver ﬁbrosis or
necroinﬂammation
We demonstrated that serum levels of M2BPGi were elevated in
AIH patients compared those with chronic hepatitis C as well as
those with another autoimmune disease, SLE (Fig. 5). To evaluate
whether serum M2BPGi correlated with liver histology, we
evaluated serum M2BPGi levels in AIH patients sub-grouped
according to the staging of liver ﬁbrosis (Fig. 6). The mean
M2BPGi values in each ﬁbrosis stage (F0–F4) were 4.0±3.0 COI
in F0–F1, 4.7±2.4 COI in F2, and 6.1±4.3 COI in F3+F4. The
values of M2BPGi were increased according to the stage of liver
ﬁbrosis (Fig. 6). The M2BPGi values at each liver inﬂammation
grading (A1–A3) were also evaluated by necroinﬂammatory
grade (Fig. 6). The mean M2BPGi values for each necroin-
ﬂammatory grade (A1–A3) were 3.3±3.4 COI in A1, 4.6±3.0
COI in A2, and 5.4±3.8 COI in A3. The values of M2BPGi were
increased according to the grade of liver inﬂammation (Fig. 6).
Whereas there was no signiﬁcant correlation between serum
levels of sICAM-1/IP-10 and liver ﬁbrosis or inﬂammation scores
(Fig. 7). In addition, there was a correlation between sICAM-1 or
IP-10 levels and those of M2BPGi in AIH patients (Fig. 8). We
stratiﬁed AIH patients by excluding patients with advance liver
ﬁbrosis stage (>F3) to minimize the effect of liver ﬁbrosis against
the values of circulating M2BPGi. We found a strong correlation
between serum sICAM-1 or IP-10 levels and M2BPGi in AIH
patients without advance liver ﬁbrosis stage (Fig. 9).
3.5. Changes in M2BPGi by corticosteroid therapy
Circulating levels of M2BPGi were measured before and after
corticosteroid therapy in paired serum samples from 57 AIH
Figure 1. Hierarchical clustering with a Spearman correlation heat map of
serum cytokine levels between active AIH before treatment and inactive
autoimmune hepatitis (AIH) after treatment. AIH = autoimmune hepatitis.
Figure 2. Serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and IP-10 in autoimmune hepatitis (AIH) patients (n=77), patients with chronic
hepatitis C (HCV, n=32) and patients with SLE (n=27). The vertical lines indicate the range and the horizontal boundaries of the boxes represent the ﬁrst and third
quartiles. Results were compared by non-parametric Mann–Whitney U test. IP-10= interferon-g-inducible protein 10, sICAM-1=soluble intercellular adhesion
molecule-1. AIH = autoimmune hepatitis.
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patients. Serum levels of sICMA-1 and IP-10were downregulated
by corticosteroid therapy in AIH patients (Fig. 10A, B).
Similarly, M2BPGi was upregulated in untreated AIH patients
and downregulated following glucocorticoid treatment of the
same patients (Fig. 10C). There was a signiﬁcant difference in
M2BPGi values before and after corticosteroid therapy in AIH
patients.
4. Discussion
A comparative study of serum levels of various cytokines and
chemokines in AIH patients before and after steroid therapy
revealed the increased expression of a series of proinﬂammatory
cytokines and chemokines. Among these cytokines/chemokines,
we focused on combinational biomarkers for the acute phase of
AIH consisting of IP-10 and sICAM-1. In our study, IP-10 levels
were correlated with AIH disease severity, which is in line with
previous studies of other liver diseases. Intracellular adhesion
molecule-1 (ICAM-I), a member of the immunoglobulin (Ig)
supergene family,[21] plays an important role in the recruitment
of various inﬂammatory cells, antigen presentation and
lymphocyte cytotoxicity.[22] Inﬂammatory cytokines, such as
TNF-a and IL-1b enhance the expression of ICAM-I on
hepatocytes.[23] Levels of sICAM-1 are increased in inﬂamma-
tory conditions of the liver indicating they might be related to
the severity of liver disease or response to treatment.[24] Our
demonstration of elevated sICAM-1 levels may be explained by
the cytokine-induced upregulation of ICAM-1 expression by
lymphocyte inﬁltration and inﬂamed or damaged hepatocytes.
These ﬁndings suggest that elevated levels of circulating sICAM-
1 could be linked with cytokine-mediated liver inﬂammatory
process in AIH.
Figure 3. Correlations between serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and ALT/TB levels in patients with autoimmune hepatitis (AIH).
Serum sICAM-1 signiﬁcantly correlated with serum ALT and TB level. Statistics and regression line are represented by the solid line. AIH = autoimmune hepatitis,
ALT=alanine aminotransferase, sICAM-1=soluble intercellular adhesion molecule-1, TB= total bilirubin.
Figure 4. Correlations between serum levels of IP-10 and ALT/TB levels in patients with autoimmune hepatitis (AIH). Serum IP-10 signiﬁcantly correlated with
serum ALT level. Statistics and regression line are represented by the solid line. AIH = autoimmune hepatitis, ALT=alanine aminotransferase, IP-10= interferon-
g-inducible protein 10, TB= total bilirubin.
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Of note, serum sICAM-1 or IP-10 levels correlated with
circulating l M2BPGi levels in the present study. Previous
studies demonstrated that M2BPGi was a prognostic factor for
liver ﬁbrosis in various chronic liver diseases.[9] However, the
interactions of serum M2BPGi and levels of serum cytokines in
autoimmune liver diseases remain unclear. To the best of our
knowledge, this is the 1st study to investigate the relationship
between serum M2BPGi and proinﬂammatory cytokines in
patients with liver diseases. Our data indicate that serum
M2BPGi values are elevated in patients with AIH, and that they
correlate with serum IP-10 and sICAM-1 levels, which
are involved in promoting active AIH from inactive AIH.
Furthermore, elevated serum M2BPGi levels were rapidly
reduced following immunosuppressive treatment in AIH
patients. These ﬁndings suggest that M2BPGi may not be just
a liver ﬁbrosis marker but also a useful biomarker for immune-
mediated hepatic injury. Umemura et al reported that M2BPGi
levels were signiﬁcantly correlated with histological activity
grade in PBC patients.[12] Mishikawa et al demonstrated that
M2BPGi was a useful predictor for liver histological ﬁndings in
patients with AIH.[13] Our results demonstrating that M2BPGi
values correlated with liver inﬂammation in AIH are consistent
with the ﬁnding of Nishikawa et al.[12] In our study, elevated
levels of the liver-speciﬁc biomarker M2BPGi were not
increased in patients with SLE, another autoimmune disorder.
However, M2BPGi values correlated with the circulating levels
of IP-10 and sICAM-1 in SLE patients. These results may
increase our understanding of the role of M2BPGi in
autoimmune disease and its implications in the cytokine
network. M2BPGi is a useful biomarker for liver ﬁbrosis in
chronic liver disease.[25] It is unclear whether circulating
M2BPGi values are inﬂuenced by immune-mediated hepatic
inﬂammation in AIH. Our data conﬁrmed that circulating
M2BPGi values correlated with autoimmune-mediated liver
damage in AIH and that its levels were rapidly reduced by
steroid treatment. These ﬁndings suggest that M2BPGi is likely
to reﬂect other factors not limited to liver ﬁbrosis such as
hepatic inﬂammation or injury. Hepatic stellate cells (HSCs)
secrete M2BPGi, which may serve as a messenger between HSCs
and Kupffer cells via Mac2, which is expressed in Kupffer
cells.[26] Therefore, M2BPGi is a surrogate marker for assessing
HSC activation. Our ﬁndings suggest that cytokines/chemo-
kines are implicated in HSC activation, M2BPGi induction and
the interaction between HSCs and Kupffer cells via M2BPGi.
These ﬁndings also suggest that M2BPGi levels are inﬂuenced by
hepatic inﬂammation and decreased following immunosuppres-
sive treatment reﬂecting immune-mediated liver inﬂammation
and damage in AIH.
There were limitations in our study. First, this was a
retrospective study. Second, liver biopsy has a limitation of
Figure 5. Serum levels of M2BPGi in autoimmune hepatitis (AIH) patients
(n=77), patients with chronic hepatitis C (HCV, n=32) and patients with
systemic lupus erythematosus (SLE, n=27). The vertical lines indicate the
range and the horizontal boundaries of the boxes represent the 1st and 3rd
quartiles. Results were compared by non-parametric Mann–Whitney U test.
AIH = autoimmune hepatitis, M2BPGi=Mac-2 binding protein glycosylation
isomer.
Figure 6. Serum levels of M2BPGi increased according to liver ﬁbrosis stage and liver inﬂammation grading. The vertical lines indicate the range and the horizontal
boundaries of the boxes represent the ﬁrst and third quartile. Results were compared by non-parametric Mann–Whitney U test. M2BPGi=Mac-2 binding protein
glycosylation isomer.
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Figure 7. Serum levels of sICAM-1/IP-10 and according to liver ﬁbrosis stage or inﬂammatory grading. The vertical lines indicate the range and horizontal
boundaries of the boxes represent the 1st and 3rd quartile. Results were compared by non-parametric Mann–WhitneyU test. IP-10= interferon-g-inducible protein
10, sICAM-1=soluble intercellular adhesion molecule-1.
Figure 8. Correlations between serum levels of sICAM-1/IP-10 and serum M2BPGi levels in patients with autoimmune hepatitis (AIH). Serum sICAM-1 and IP-10
signiﬁcantly correlated with serumM2BPGi levels. Statistics and regression line are represented by the solid line. AIH = autoimmune hepatitis, COI: cutoff index, IP-
10= interferon-g-inducible protein 10, sICAM-1=soluble intercellular adhesion molecule-1, M2BPGi=Mac-2 binding protein glycosylation isomer.
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sampling error for assessing the degree of ﬁbrosis and liver
inﬂammation. Third, our sample size was relatively small for
analysis.
5. Conclusion
Serum levels of M2BPGi were increased in patients with
untreated AIH and were decreased following steroid treatment
resulting in a clinical improvement. This marker might reﬂect
liver ﬁbrosis as well as autoimmune-mediated hepatic inﬂamma-
tion in parallel to the induction of hepatitis-related inﬂammatory
cytokines.
Author contributions
Conceptualization:Kiyoshi Migita.
Data curation: Yoshiro Horai, Hideko Kozuru, Seigo Abiru,
Kazumi Yamasaki, Atsumasa Komori, Yuya Fujita,
Tomoyuki Asano, Shuzo Sato, Eiji Suzuki, Naoki Matsuoka,
Hiroko Kobayashi, Hiroshi Watanabe, Atsushi Naganuma,
Noriaki Naeshiro, Kaname Yoshizawa, Hajime Ohta,
Hironori Sakai,Masaaki Shimada, HideoNishimura,Minoru
Tomizawa, Keisuke Ario, Haruhiko Yamashita, Hiroshi
Kamitsukasa, Hiroshi Kohno.
Formal analysis: Tomohiro Koga.
Figure 9. Correlations between serum levels of sICAM-1/IP-10 and serum levels of M2BPGi in autoimmune hepatitis (AIH) patients stratiﬁed by excluding patients
with advance liver ﬁbrosis stage (> F3). Serum sICAM-1 level signiﬁcantly correlated with serumM2BPGi levels. Statistics and regression line are represented by the
solid line. AIH = autoimmune hepatitis, COI: cutoff index, IP-10= interferon-g-inducible protein 10, sICAM-1=soluble intercellular adhesion molecule-1, M2BPGi=
Mac-2 binding protein glycosylation isomer.
Figure 10. Changes in individual sICAM-1, IP-10 and M2BPGi values before and after (4weeks) steroid treatment in 57 autoimmune hepatitis (AIH) patients. Paired
samples from the same subjects were compared by Wilcoxon signed-rank test. COI: cutoff index. IP-10= interferon-g-inducible protein 10, M2BPGi=Mac-2
binding protein glycosylation isomer.
Migita et al. Medicine (2018) 97:50 Medicine
8
Investigation: Minoru Nakamura, Hiroshi Furukawa.
Supervision: Atsushi Takahashi, Atsushi Kawaami, Hiromasa
Ohira, Hiroshi Yatsuhashi.
References
[1] Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54–66.
[2] Ohira H, Abe K, Takahashi A, et al. Autoimmune hepatitis: recent
advances in the pathogenesis and new diagnostic guidelines in Japan.
Intern Med 2015;54:1323–8.
[3] Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum
alanine aminotransferase levels improves the prognosis of type 1
autoimmune hepatitis. J Hepatol 2005;43:951–7.
[4] Migita K, Watanabe Y, Jiuchi Y, et al. Evaluation of risk factors for the
development of cirrhosis in autoimmune hepatitis: Japanese NHO-AIH
prospective study. J Gastroenterol 2011;46(Suppl 1):56–62.
[5] Migita K, Watanabe Y, Jiuchi Y, et al. Japanese NHO-Liver-network
study groupHepatocellular carcinoma and survival in patients with
autoimmune hepatitis (Japanese National Hospital Organization-
autoimmune hepatitis prospective study). Liver Int 2012;32:837–44.
[6] Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol
2009;27:147–63.
[7] Longhi MS, Ma Y, Mieli-Vergani G, et al. Aetiopathogenesis of
autoimmune hepatitis. J Autoimmun 2010;34:7–14.
[8] Kamijo A, Yoshizawa K, Joshita S, et al. Cytokine proﬁles affecting the
pathogenesis of autoimmune hepatitis in Japanese patients. Hepatol Res
2011;41:350–7.
[9] Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker,
glycosylated Wisteria ﬂoribunda agglutinin-positive Mac-2 binding
protein (WFA(+)-M2BP), for assessing liver ﬁbrosis. J Gastroenterol
2015;50:76–84.
[10] Abe M, Miyake T, Kuno A, et al. Association between Wisteria
ﬂoribunda agglutinin-positive Mac-2 binding protein and the ﬁbrosis
stage of non-alcoholic fatty liver disease. J Gastroenterol 2015;50:
776–84.
[11] Morio K, Imamura M, Daijo K, et al. Wisteria ﬂoribunda agglutinin
positive Mac-2-binding protein level increases in patients with acute liver
injury. J Gastroenterol 2017;52:1252–7.
[12] Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria ﬂoribunda
agglutinin-positiveMac-2-binding protein level predicts liver ﬁbrosis and
prognosis in primary biliary cirrhosis. Am J Gastroenterol 2015;110:
857–64.
[13] Nishikawa H, Enomoto H, Iwata Y, et al. Clinical signiﬁcance of serum
Wisteria ﬂoribunda agglutinin positive Mac-2-binding protein level and
high-sensitivity C-reactive protein concentration in autoimmune hepati-
tis. Hepatol Res 2016;46:613–21.
[14] Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune
Hepatitis Group report: review of criteria for diagnosis of autoimmune
hepatitis. J Hepatol 1999;31:929–38.
[15] Koga T, Migita K, Sato S, et al. Multiple serum cytokine proﬁling to
identify combinational diagnostic biomarkers in attacks of familial
Mediterranean fever. Medicine 2016;95:e3449.
[16] Breiman L. Random forests. Mach Learn 2001;45:5–32.
[17] Kokkonen H, Soderstrom I, Rocklov J, et al. Up-regulation of cytokines
and hemokines predates the onset of rheumatoid arthritis. Arthritis
Rheum 2010;62:383–91.
[18] Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of
Wisteria ﬂoribunda agglutinin-positive human Mac-2 binding protein
predict the development of hepatocellular carcinoma in hepatitis C
patients. Hepatology 2014;60:1563–70.
[19] Desmet VJ, Gerber M, Hoofnagle JH, et al. Classiﬁcation of chronic
hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–20.
[20] Liberal R, Longhi MS, Mieli-Vergani G, et al. Pathogenesis of
autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011;25:
653–64.
[21] Staunton DE, Dustin ML, Erickson HP, et al. The arrangement of the
immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-
1 and rhinovirus. Cell 1990;61:243–54.
[22] Meyer DM, Dustin ML, Carron CP. Characterization of intercellular
adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of
lymphocyte function-associated molecule-1 interaction with ICAM-1.
J Immunol 1995;155:3578–84.
[23] Kaplanski G, Farnarier C, Payan MJ, et al. Increased levels of soluble
adhesion molecules in the serum of patients with hepatitis C. Correlation
with cytokine concentrations and liver inﬂammation and ﬁbrosis. Dig
Dis Sci 1997;42:2277–84.
[24] Spahr L, Rubbia-Brandt L, Pugin J, et al. Rapid changes in alcoholic
hepatitis histology under steroids: correlation with soluble intercellular
adhesion molecule-1 in hepatic venous blood. J Hepatol 2001;35:582–9.
[25] Ito K, Murotani K, Nakade Y, et al. Serum Wisteria ﬂoribunda
agglutinin-positive Mac-2-binding protein levels and liver ﬁbrosis: a
meta-analysis. J Gastroenterol Hepatol 2017;32:1922–30.
[26] Bekki Y, Yoshizumi T, Shimoda S, et al. Hepatic stellate cells secreting
WFA+ -M2BP: Its role in biological interactions with Kupffer cells. J
Gastroenterol Hepatol 2017;32:1387–93.
Migita et al. Medicine (2018) 97:50 www.md-journal.com
9
